Endocrinology

Latest News

©CLIPAREA/shutterstock.com
Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data

February 28th 2024

Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.

Viking Therapeutics Dual GIP/GLP-1 Mimetic Drives Weight Loss of Up to 14.7% in Phase 2 Findings / image credit weight loss cartoon: ©Design36/Shutterstock.com
Viking Therapeutics Dual GIP/GLP-1 Mimetic Drives Weight Loss of Up to 14.7% in Phase 2 Findings

February 28th 2024

Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants / image credit liver disease stages: ©wowow.stock.adobe.com
Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants

February 27th 2024

Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock
Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose

February 23rd 2024

Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose / image credit: ©New Africa/AdobeStock
Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose

February 21st 2024

Latest CME Events & Activities
© 2024 MJH Life Sciences

All rights reserved.